Jennison Associates LLC lowered its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 12.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 892,651 shares of the company’s stock after selling 126,362 shares during the period. Jennison Associates LLC owned 4.24% of Corvus Pharmaceuticals worth $14,229,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. TIAA CREF Investment Management LLC boosted its holdings in Corvus Pharmaceuticals by 43.3% in the first quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock worth $149,000 after acquiring an additional 2,170 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Corvus Pharmaceuticals by 29.3% in the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock worth $112,000 after acquiring an additional 2,105 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock worth $115,000 after acquiring an additional 9,099 shares in the last quarter. Alliancebernstein L.P. bought a new position in Corvus Pharmaceuticals in the second quarter worth approximately $175,000. Finally, California State Teachers Retirement System boosted its holdings in Corvus Pharmaceuticals by 121.2% in the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock worth $181,000 after acquiring an additional 8,200 shares in the last quarter. Institutional investors and hedge funds own 82.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/jennison-associates-llc-sells-126362-shares-of-corvus-pharmaceuticals-inc-crvs/1711606.html.

Several research analysts have issued reports on CRVS shares. Wedbush started coverage on Corvus Pharmaceuticals in a report on Wednesday, August 2nd. They issued an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research lowered Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Finally, Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price target on the stock in a report on Wednesday, August 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Corvus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $20.25.

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ CRVS) opened at $11.27 on Friday. Corvus Pharmaceuticals, Inc. has a 52 week low of $8.27 and a 52 week high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. analysts anticipate that Corvus Pharmaceuticals, Inc. will post -2.82 EPS for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.